ArticleCommunity mental health journal2026
Deprescribing Psychiatric Medications in Youth: A Feasibility Study.
Article in Community mental health journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rates of psychiatric medications prescribed to U.S. youth have increased substantially and stakeholders are increasingly concerned. We tested the feasibility of a novel intervention that combines shared decision making and a structured deprescribing protocol during routine outpatient care with youth. Five clinicians delivered the intervention to youth 6 to 17 years old receiving three or more psychiatric medications or an off-label antipsychotic. Families completed assessments at baseline, 18- and 30-weeks. We collected data via surveys, medical records, and qualitative interviews. We enrolled 31 youth, 29 received the intervention, and 13 of the 29 (45%) chose to deprescribe. Eleven of those 13 reduced their dose or stopped completely; 2 returned to their original dose. Of the 13 that agreed to deprescribe, the mean dose-weighted medication use reduced from 3.9 (SD=1.38) to 2.9 (SD=1.41), and the mean number of medication reactions reduced from 1.3 (SD=2.21) to 0.3 (SD=0.48). In the 16 participants who chose not to deprescribe, the mean dose-weighted medication use and medication reactions reduced from 3.4 (SD=0.89) to 3.2 (SD=1.32) and 0.6 (SD=0.89) to 0.0 (SD=0.0), respectively. Youth functioning remained similar across groups. There were no study-related serious adverse events. Clinicians and caregivers considered the intervention feasible, valuable, and effective. Our intervention and procedures were feasible in real-world community settings. The intervention shows promising findings related to safety and effectiveness. Trial registration: Our study was retrospectively registered with ClinicalTrials.gov. NCT # pending.
Indexed as
Identifiers
42525221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.